📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Zim Laboratories Allots 47.64 Lakh Shares to Florintree Trinex LLP, Raising ₹35 Crore
Zim Laboratories has successfully completed the allotment of 47,64,497 equity shares to Florintree Trinex LLP on a preferential basis. The shares were issued at a price of ₹73.46 each, resulting in a total capital infusion of approximately ₹35 crore. This allotment increases the company's paid-up equity share capital from ₹48.74 crore to ₹53.50 crore. Post-allotment, Florintree Trinex LLP holds an 8.91% stake in the company, marking the entry of a significant non-promoter investor.
Key Highlights
Allotted 47,64,497 equity shares at an issue price of ₹73.46 per share
Total fundraise aggregates to approximately ₹34.99 crore from a single investor
Paid-up equity capital expanded from ₹48.74 crore to ₹53.50 crore
Investor Florintree Trinex LLP now holds an 8.91% stake in the company
Issue price includes a premium of ₹63.46 per share over the face value of ₹10
💼 Action for Investors
The capital infusion and entry of a significant institutional-style investor are positive signals for the company's growth prospects. Investors should monitor the company's upcoming quarterly results to see how this capital is deployed for expansion or debt reduction.
Zim Laboratories Q3 FY26 Revenue at INR 1,087 Mn; EU-GMP Audit Slated for H1 FY27
Zim Laboratories reported a total operating income of INR 1,087 million for Q3 FY26, showing steady sequential improvement and a 23.2% YoY growth in exports. The company's EBITDA stood at INR 145 million with a margin of 13.4%, while Profit After Tax reached INR 44 million. A critical focus remains on the EU-GMP remediation process, with a regulatory audit expected in H1 FY27 to unlock high-value regulated markets. Additionally, the company raised INR 35 crores via a preferential issue to fund capacity expansion and regulatory compliance.
Key Highlights
Total operating income reached INR 1,087 million in Q3 FY26, driven by strong export traction.
Export revenue grew 23.2% YoY to INR 906 million, contributing 88% of total operating income.
Innovative NIP and OTF product segments contributed INR 132 million, representing 12.2% of revenue.
Completed a preferential issue of INR 35 crores for pancreatin block expansion and CAPA implementation.
EU-GMP remediation audit tentatively scheduled for H1 FY27 (June-July 2026) to address previous non-compliance.
💼 Action for Investors
Investors should closely track the outcome of the EU-GMP audit in early FY27, as successful certification is the key catalyst for launching high-margin products in Europe. While the base export business is growing, the stock's re-rating depends on clearing regulatory hurdles and scaling the innovative NIP portfolio.
ZIM Laboratories Shareholders Approve Preferential Issue of Equity Shares
Zim Laboratories Limited held an Extraordinary General Meeting on February 16, 2026, where shareholders approved a special resolution for the issuance of equity shares via a preferential issue on a private placement basis. The resolution was passed with an overwhelming majority, receiving 99.99% of the total votes in favor. A total of 30.74 million votes were polled, representing approximately 63.07% of the company's total outstanding shares. This approval paves the way for the company to raise capital for its strategic initiatives.
Key Highlights
Shareholders approved the issuance of equity shares through a preferential issue on a private placement basis via a special resolution.
The resolution received 99.9896% votes in favor (30,734,942 votes) and only 0.0104% against.
Total voter turnout represented 63.07% of the total 48,735,814 outstanding shares.
Promoter group participation was 100%, with all 16,207,980 promoter shares voting in favor of the resolution.
Public non-institutional shareholders showed strong support with 99.978% of their polled votes in favor.
💼 Action for Investors
Investors should monitor subsequent filings for details on the issue price and the specific allottees to evaluate the impact of equity dilution. The strong shareholder mandate indicates high confidence in the company's fundraising and growth strategy.
Zim Laboratories Conducts EGM for Equity Issuance via Preferential Issue
Zim Laboratories Limited held its first Extraordinary General Meeting (EGM) for FY 2025-26 on February 16, 2026, to seek shareholder approval for a preferential issue of equity shares. The meeting, attended by 42 members via video conferencing, focused on a special resolution for private placement of equity. Chairman Dr. Anwar Siraj Daud addressed the shareholders regarding the proposed capital infusion and provided general business updates. The final voting results are pending the scrutinizer's report and will be disclosed to the exchanges shortly.
Key Highlights
Proposed a special resolution for the issuance of equity shares via preferential issue on a private placement basis.
The EGM was conducted on February 16, 2026, with 42 shareholders participating through video conferencing.
Chairman Dr. Anwar Siraj Daud provided updates on the company's strategic direction and the rationale for the fundraise.
Voting was facilitated through remote e-voting and an electronic system during the meeting, with results to be announced within statutory timelines.
The meeting was attended by key management personnel, including the CFO, Company Secretary, and representatives from Deloitte Haskins & Sells LLP.
💼 Action for Investors
Investors should monitor the upcoming disclosure of the voting results and specific details regarding the pricing and allottees of the preferential issue. This capital raise is a significant event that could support future expansion or debt reduction.
Zim Laboratories Q3 PAT Rises 10% YoY to ₹4.4 Cr; Announces Expansion into Chile
Zim Laboratories reported a recovery in Q3 FY26 with revenue growing 12.8% YoY to ₹108.66 crore. Net profit for the quarter stood at ₹4.40 crore, up 10% from ₹4.00 crore in the same period last year, showing a significant turnaround from the loss reported in the previous quarter. However, the nine-month performance remains weak, with PAT dropping over 71% YoY to ₹2.10 crore. Additionally, the company is expanding its footprint into the LATAM region by incorporating a subsidiary in Chile.
Key Highlights
Revenue from operations increased 12.8% YoY to ₹108.66 crore in Q3 FY26.
Net Profit (PAT) for the quarter rose 10% YoY to ₹4.40 crore, recovering from a loss of ₹0.42 crore in Q2 FY26.
9M FY26 PAT stands at ₹2.10 crore, a sharp decline from ₹7.28 crore in the previous year's nine-month period.
Board approved a $15,000 investment to set up a new wholly-owned subsidiary in Chile.
Finance costs rose to ₹3.43 crore in Q3 FY26 compared to ₹2.73 crore in Q3 FY25.
💼 Action for Investors
Investors should monitor if the Q3 recovery marks a permanent turnaround or a seasonal spike, given the weak cumulative nine-month performance. The expansion into Chile is a positive strategic move, though the initial capital commitment is very small.
ZIMLAB Q3FY26 Revenue Grows 12.8% YoY to ₹1,087 Mn; Recovers to Profitability
Zim Laboratories reported a strong sequential recovery in Q3FY26, with revenue growing 22.5% QoQ to ₹1,087 Mn and EBITDA rising 86% QoQ to ₹145 Mn. The company returned to a PAT of ₹44 Mn after a loss in Q2, largely driven by a 93% QoQ surge in the Nutraceutical segment following the resolution of currency issues in legacy markets. Despite the quarterly recovery, 9MFY26 PAT remains down 71.2% YoY at ₹21 Mn. Additionally, the board approved a ₹35 crore preferential fundraise to Florintree Trinex LLP at ₹73.46 per share.
Key Highlights
Q3FY26 Total Operating Income rose 12.8% YoY to ₹1,087 Mn with EBITDA margins at 13.4%.
Nutraceutical business revenue increased 93% QoQ to ₹300 Mn, contributing 28% of total revenue.
Board approved a preferential equity issuance of ₹35 crore to Florintree Trinex LLP at ₹73.46 per share.
R&D spend for 9MFY26 stood at ₹230 Mn, representing 8.6% of Total Operating Income.
CAPA remediation is nearing completion with the facility expected to be ready for inspection from March 2026.
💼 Action for Investors
Investors should closely monitor the outcome of the EU GMP inspection scheduled for March 2026, as it is critical for the 'Star Product' launches in developed markets. While the Q3 recovery is positive, the significant YoY decline in 9-month profitability suggests a need for caution until margin stability is sustained.
Zim Laboratories to Expand in LATAM with New Subsidiary in Chile
Zim Laboratories Limited has received board approval to incorporate a wholly owned subsidiary in Chile, tentatively named ZIM Laboratories SpA. The company plans to invest up to USD 15,000 in the share capital of this new entity to facilitate business development in the LATAM region. This move marks a strategic step toward establishing a direct presence in South American pharmaceutical markets. While the initial investment is small, it provides a platform for future growth and regulatory filings in the region.
Key Highlights
Incorporation of a 100% wholly owned subsidiary in Chile, LATAM region.
Initial investment approved for an amount up to USD 15,000.
The new entity will focus on the expansion and development of the pharmaceutical business.
Promoters Dr. Anwar Daud and Mr. Zulfiquar Kamal to be appointed as Directors of the subsidiary.
The transaction will be a cash consideration and is currently not a related party transaction.
💼 Action for Investors
Investors should view this as a low-risk strategic entry into a new geography. Monitor future updates regarding product registrations or revenue contributions from the LATAM region to assess the success of this expansion.
ZIM Laboratories Q3 PAT Rises 10% YoY to ₹4.4 Cr; Strong Recovery from Q2 Loss
ZIM Laboratories reported a significant sequential recovery in Q3 FY26, with consolidated revenue growing 12.8% YoY to ₹108.66 crore. Net profit for the quarter stood at ₹4.40 crore, up from ₹4.00 crore in the same period last year and a sharp turnaround from the ₹0.42 crore loss in Q2 FY26. Despite the quarterly recovery, the nine-month (9M) performance remains pressured, with PAT down 71% YoY at ₹2.10 crore. Finance costs and other expenses have trended higher throughout the year, impacting cumulative margins.
Key Highlights
Revenue from operations grew 12.8% YoY to ₹108.66 crore in Q3 FY26.
Net profit recovered to ₹4.40 crore in Q3 FY26 from a loss of ₹42.46 lakhs in the preceding quarter.
9-month PAT stands at ₹2.10 crore, a sharp decline from ₹7.28 crore in the previous year's 9M period.
Finance costs for the 9-month period increased to ₹9.89 crore from ₹8.48 crore YoY.
Total comprehensive income for Q3 FY26 was ₹5.26 crore, aided by positive other comprehensive income of ₹86.67 lakhs.
💼 Action for Investors
The sharp sequential recovery in profitability suggests that the operational headwinds faced in the first half of the year may be easing. Investors should monitor if the company can maintain these improved margins in the final quarter to confirm a full turnaround.
ZIM Laboratories Q3 PAT Rises 10% YoY to ₹4.4 Cr; Announces Expansion into Chile
ZIM Laboratories reported a 12.8% YoY growth in revenue for Q3 FY26, reaching ₹108.66 crore. While the quarterly profit after tax (PAT) grew by 9.9% YoY to ₹4.40 crore, the cumulative nine-month performance remains under pressure with PAT down 71% compared to the previous year. Sequentially, the company showed a significant recovery, turning a profit after a loss in the preceding quarter. Additionally, the board has approved a strategic entry into the Latin American market by establishing a wholly-owned subsidiary in Chile.
Key Highlights
Revenue from operations increased by 12.8% YoY to ₹108.66 crore in Q3 FY26.
Net Profit for the quarter stood at ₹4.40 crore, compared to ₹4.00 crore in the same period last year.
Strong sequential recovery from a net loss of ₹42.46 lakhs in Q2 FY26 to a profit in Q3 FY26.
Nine-month PAT (9M FY26) declined sharply to ₹2.10 crore from ₹7.28 crore in 9M FY25.
Board approved an investment of up to USD 15,000 to incorporate a new subsidiary in Chile, LATAM region.
💼 Action for Investors
Investors should note the strong sequential turnaround in Q3, but remain cautious as the overall nine-month profitability is significantly lower than the previous year. The expansion into Chile is a positive long-term strategic step, though the initial investment is small.
Zim Laboratories Appoints Vikrant Bendre as President - International Business & Strengthens SMP
Zim Laboratories has appointed Mr. Vikrant Bendre as President of International Business, leveraging his 26+ years of experience at major firms like JB Chemicals and Ipca Laboratories. The company also elevated Mr. Jitendra Pandey (VP-HR) and Mr. Sridhar Reddy (VP-Quality Assurance) to Senior Management Personnel status. Mr. Reddy’s 29 years of experience in handling US FDA and UK MHRA audits is particularly significant for the company's regulatory standing. These strategic moves are designed to bolster the company's global footprint and operational governance.
Key Highlights
Appointment of Vikrant Bendre as President – International Business with 26 years of global P&L experience.
Sridhar Reddy (VP-QA) brings 29 years of experience in sterile and non-sterile pharma manufacturing and regulatory audits.
Jitendra Pandey (VP-HR) categorized as SMP with nearly 20 years of experience from Alkem and John Deere.
The leadership additions focus on scaling international operations and maintaining high-standard quality compliance.
💼 Action for Investors
Investors should view these high-level appointments from larger pharma peers as a positive sign for the company's growth and compliance scaling. Monitor for improved export revenues and successful regulatory audit outcomes in future quarters.
Zim Laboratories to Raise ₹35 Crore via Preferential Issue to Florintree Trinex LLP
Zim Laboratories Limited has called for an Extraordinary General Meeting (EGM) on February 16, 2026, to approve a preferential equity issuance. The company intends to raise approximately ₹35 crore by issuing 47,64,497 equity shares to Florintree Trinex LLP, a non-promoter investor. The shares are priced at ₹73.46 each, which includes a premium of ₹63.46 per share. This capital infusion is expected to strengthen the company's balance sheet and fund future growth requirements.
Key Highlights
Issuance of up to 47,64,497 equity shares at a price of ₹73.46 per share
Total fundraise amount capped at approximately ₹34,99,99,950 (₹35 crore)
The entire issue is allocated to Florintree Trinex LLP, a non-promoter entity
Relevant date for floor price determination was set as January 16, 2026
EGM to be held on February 16, 2026, with remote e-voting starting February 13
💼 Action for Investors
Investors should view this as a positive development as it brings in institutional capital, though they should account for the resulting equity dilution. Monitor the company's subsequent disclosures regarding the specific utilization of these funds for expansion or debt reduction.
Zim Laboratories to Raise ₹35 Crore via Preferential Issue to Florintree Trinex LLP
The Board of Zim Laboratories has approved a preferential issue of 47,64,497 equity shares to Florintree Trinex LLP at a price of ₹73.46 per share. This transaction aims to raise approximately ₹35 crore in cash consideration from a non-promoter investor. Post-allotment, Florintree Trinex LLP will hold an 8.91% stake in the company. An Extra-ordinary General Meeting (EGM) is scheduled for February 16, 2026, to obtain shareholder approval for this issuance.
Key Highlights
Issuance of up to 47,64,497 equity shares at a fixed price of ₹73.46 per share
Total fundraise amount aggregates to approximately ₹34,99,99,950
Florintree Trinex LLP to emerge as a significant non-promoter shareholder with an 8.91% stake
Extra-ordinary General Meeting (EGM) convened for February 16, 2026, for shareholder voting
The capital infusion is intended to support the company's growth and financial requirements
💼 Action for Investors
Investors should view this as a positive development as it brings in growth capital and a professional investor. Monitor the EGM outcome and subsequent updates on how the management intends to deploy this capital for expansion.
Zim Laboratories to Raise ₹35 Crore via Preferential Issue to Florintree Trinex LLP
Zim Laboratories has approved a preferential issue of 47,64,497 equity shares to Florintree Trinex LLP, a non-promoter entity. The shares are priced at ₹73.46 each, resulting in a total capital infusion of approximately ₹35 crore. Post-allotment, the investor will hold an 8.91% stake in the company. The proposal is subject to shareholder approval at an Extra-ordinary General Meeting (EGM) scheduled for February 16, 2026.
Key Highlights
Issuance of up to 47,64,497 equity shares at a price of ₹73.46 per share.
Total fundraise aggregates to approximately ₹34.99 crore.
Investor Florintree Trinex LLP to hold an 8.91% stake post-issue.
Extra-ordinary General Meeting (EGM) for shareholder approval set for February 16, 2026.
The fundraise is conducted on a private placement basis to a non-promoter group.
💼 Action for Investors
Investors should monitor the company's plans for utilizing this capital and note the ~9% equity dilution. The entry of a professional investment entity like Florintree is typically a positive signal for mid-cap pharma companies.
Zim Laboratories Receives CDSCO Approval for Naproxen + Esomeprazole FDC Capsules
Zim Laboratories has secured approval from the Central Drugs Standard Control Organisation (CDSCO) to manufacture and market a novel Fixed Dose Combination (FDC) of Naproxen and Esomeprazole. The product utilizes the company's proprietary drug delivery technology, combining delayed-release minitablets and pellets in a single capsule. A commercial supply agreement is already in place with an Indian pharmaceutical company for this product. The company expects a commercial launch in India by FY 2026-27, strengthening its position in the pain management and gastro-protective segments.
Key Highlights
Received CDSCO approval for Naproxen Delayed Release (375mg/500mg) and Esomeprazole (20mg) FDC capsules.
Product developed using proprietary drug delivery systems including minitablets and pellets.
Commercial supply agreement already signed with a domestic pharmaceutical partner.
Targeting commercial launch in the Indian market during FY 2026-27.
Indicated for symptomatic treatment of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis.
💼 Action for Investors
Investors should view this as a positive validation of ZIMLAB's R&D capabilities and New Innovative Product (NIP) pipeline. Monitor the execution of the supply agreement and the subsequent revenue impact starting FY27.